Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Royalty Pharma ( (RPRX) ) is now available.
Royalty Pharma announced key achievements in 2024, including expected portfolio receipts of approximately $2.8 billion and growth in royalty receipts by 13%. The company completed eight royalty transactions worth $2.8 billion and introduced a $3 billion share repurchase program. Royalty Pharma also plans to acquire its external manager, RP Management, for $1.1 billion, which will save more than $1.6 billion over ten years, enhance shareholder alignment, and improve governance. This internalization is seen as a strategic evolution to simplify the company’s structure and increase transparency and valuation, offering long-term benefits to stakeholders.
More about Royalty Pharma
Royalty Pharma is a company operating in the pharmaceutical and healthcare industry, primarily focused on acquiring pharmaceutical royalties and investing in late-stage biopharmaceutical products. The company aims to provide capital to fund innovation in life sciences, with a market focus on royalty acquisitions from biopharmaceutical products across various therapeutic areas.
YTD Price Performance: 14.35%
Average Trading Volume: 2,910,549
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $17.38B
For an in-depth examination of RPRX stock, go to TipRanks’ Stock Analysis page.
